

Vaccine Effectiveness Study Review Tool

Please complete the survey below. Thank you!

1). Please list your name. (First name first)

2). Please state your title

3). Please indicate your organization

4). Please indicate your country of work

6). Please characterize your relationship to the AFRO-MOVE network

- ☐ Funder
☐ Scientific Steering Committee
☐ Network Secretariat
☐ VE Study Site
☐ Other

If other, please list role.

7). Please indicate the country your study site is within

Study timelines

Were relevant authorities (e.g., institutional and country leadership) supportive of the plan to evaluate vaccine effectiveness?

- ☐ Yes, fully supportive
☐ Yes, somewhat supportive
☐ No, not supportive

If applicable, please elaborate on level or context of support.

How long did it take from starting to draft the VE protocol with other investigators until submission for ethical review?

If applicable, please note any reasons for delay in drafting the VE protocol.

How long did it take from submission for human subjects / ethical review until ethics approval?

If applicable, please note any reasons for delay in submission for human subjects/ethical review to ethics approval.

How long did it take from approval until initial data collection (or data transmission, for retrospective designs)?

If applicable, please note reasons for delay on initial data collection.

How long did it take from initial data collection (or data transmission, for retrospective designs) until analysis?

If applicable, please note any reason for delay on analysis.

Study design

What was the overall design of the main analysis to estimate VE?

- ☐ Cohort, prospective
☐ Cohort, retrospective
☐ Test-negative design, outcome unknown when tested
☐ Test-negative design, outcome known when tested
☐ Other case-control design

What was the definition of the primary outcome?

(List the primary outcome (e.g., hospitalization with COVID-19))

Were SARS-CoV-2 tests provided as part of the study?

- ☐ Yes, for all participants
☐ Yes, for some participants
☐ No, for no participants

If applicable, please indicate any notes on tests and how they were provided.

How was the outcome assessed? (select all that apply)

- ☐ Data specific to the study, for all participants
☐ Access to an existing data source that already in place (e.g., medical records review)
☐ Other

Please specify how outcome was assessed.

What was the definition of the primary intervention?

(List the primary intervention for the most recent data (e.g., 'primary series', 'booster dose'). Specify if the primary intervention was defined by time since dose (for example, 7 days to 6 months).)

What was the definition of the primary referent group?

(List the primary referent group (to compare with the primary intervention) for the most recent data (e.g., 'unvaccinated') Specify if the vaccination referent group was defined by time since dose (for example, >6 months))

How was vaccination status assessed? (select all that apply)

- ☐ Self-report
- ☐ Individual verification of vaccine records
- ☐ Access to an existing data source that was already in place (e.g., national vaccine registry)

What was the population of interest?

(List the main population that an estimate would apply to (e.g., 'healthcare workers', 'national population', 'adults', 'population of region X'))

What were the inclusion criteria?

What were the exclusion criteria?

How were participants selected from the population? (select all that apply)

- ☐ Individual invitation to enroll
- ☐ Persons listed in an existing data source (e.g., medical records)
- ☐ Other

Please describe the other way in which participants were selected from the population.

Study context

During the period that the study outcome was recorded, were you aware of other evaluations of COVID-19 vaccine effectiveness were ongoing in the same country?

- ☐ No
- ☐ Yes, one
- ☐ Yes, more than one

If one or more, how was the planned analysis different to others?

During the period that the outcome was recorded, what was the availability of SARS-CoV-2 PCR tests?

- ☐ Widespread availability in clinical settings
- ☐ Some availability in clinical settings
- ☐ Limited availability in clinical settings
- ☐ Widespread availability in community settings
- ☐ Some availability in community settings
- ☐ Limited availability in community settings
- ☐ Other

If applicable, describe the availability of SARS-CoV-2 PCR tests.

During the period that the outcome was recorded, what was the availability of SARS-CoV-2 antigen tests?

- ☐ Widespread availability in clinical settings
- ☐ Some availability in clinical settings
- ☐ Limited availability in clinical settings
- ☐ Widespread availability in community settings
- ☐ Some availability in community settings
- ☐ Limited availability in community settings
- ☐ Other

If applicable, please describe the availability of SARS-CoV-2 antigen tests.

During the period that the outcome was recorded, which of the following may have led to differences in vaccine uptake for any specific groups (e.g., older, underlying conditions, no prior infection)? Select all that apply.

- ☐ Vaccine policy
 - ☐ Vaccine availability
 - ☐ Vaccine uptake
 - ☐ Unknown
-

If applicable, please specify your answer on what lead to difference in vaccine uptake for any specific groups.

During the period that the outcome was recorded, specify any groups that had prioritized vaccine uptake which may have led to differences:

During the period that the outcome was recorded, specify any groups that were told they could hold off obtaining a vaccine dose (e.g., those reporting prior infection) which may have led to differences:

Stakeholder Survey

This tool will be used to assess the establishment, role and level of engagement within the network, level of satisfaction with the performance of the network, perceived benefits from network participation, perceived challenges to the network achieving its objectives, potential changes that could be made in the future to strengthen the network, and level of interest in continuing to engage with the network. Please complete the survey below. Thank you!

Please list your name.

Please list your title.

Please indicate your organization.

Please indicate your country of work.

Please list your email address.

Please select one that most closely describes your relationship to the AFRO-MoVE Network.

- ☐ Funder
- ☐ Scientific Steering Committee
- ☐ Network Secretariat
- ☐ Vaccine Effectiveness Study Implementer
- ☐ Other Network Member

Please indicate the country the VE study you are involved in was implemented.

- ☐ Benin
- ☐ Cameroon
- ☐ Congo
- ☐ Ghana
- ☐ International
- ☐ Kenya
- ☐ Madagascar
- ☐ Malawi
- ☐ Mali
- ☐ Mozambique
- ☐ Namibia
- ☐ Niger
- ☐ Nigeria
- ☐ Senegal
- ☐ South Africa
- ☐ Tanzania
- ☐ Uganda
- ☐ Zimbabwe
- ☐ N/A

Is your study being funded by AFRO-MoVE?

- ☐ Yes
- ☐ No

Did you receive funding from any other source aside from AFRO-MoVE?

- ☐ Yes
- ☐ No

If yes, whom?

Do you feel the funding you received from AFRO-MoVE was adequate for carrying out an effective VE study?

- ☐ Yes
☐ No

Please elaborate.

Please indicate the current status of VE study you are involved with.

- ☐ Recruitment / Data Collection
☐ Data Analysis
☐ Report Writing
☐ Completed
☐ Discontinued
☐ Other

Please explain.

How frequently did you engage with the AFRO-MoVE network for the following types of activities?

	1 = Infrequent (once per quarter or less)	2 = Somewhat frequent (once per month)	3 = Very frequent (more than 1x per month)
Direct technical assistance	☐	☐	☐
Full Network meetings and workshops	☐	☐	☐
Other networking or professional development opportunities	☐	☐	☐

Please list any additional comments you may have about the frequency of engagement on activities with the AFRO-MoVE network. If none, please leave blank.

This section is intended to identify specific challenges at study sites and better understand how sites benefitted from involvement in the AFRO-MoVE Network.

	No challenge	Some challenge	Substantial challenge	Unknown
To what extent was availability of appropriately skilled staff a challenge?	☐	☐	☐	☐
	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown
To what extent did being involved in the AFRO-Move network facilitate the availability of appropriately skilled staff?	☐	☐	☐	☐

To what extent was securing funding a challenge?	No challenge ☐	Some challenge ☐	Substantial challenge ☐	Unknown ☐
To what extent did being in the AFRO-Move Network help your site secure funding?	No additional benefit ☐	Some additional benefit ☐	Substantial additional benefit ☐	Unknown ☐
To what extent was agreement on protocol design a challenge?	No challenge ☐	Some challenge ☐	Substantial challenge ☐	Unknown ☐
To what extent did being in the AFRO-Move Network help reach agreement on protocol design?	No additional benefit ☐	Some additional benefit ☐	Substantial additional benefit ☐	Unknown ☐
To what extent was timely approval of protocols a challenge?	No challenge ☐	Some challenge ☐	Substantial challenge ☐	Unknown ☐
To what extent did being in the AFRO-Move Network help ensure timely approval of protocols at your study site?	No additional benefit ☐	Some additional benefit ☐	Substantial additional benefit ☐	Unknown ☐
To what extent was time to begin implementation a challenge?	No challenge ☐	Some challenge ☐	Substantial challenge ☐	Unknown ☐
To what extent did involvement in the AFRO-Move Network improve time to begin implementation at your study site?	No additional benefit ☐	Some additional benefit ☐	Substantial additional benefit ☐	Unknown ☐
To what extent was acceptability of study implementation a challenge?	No challenge ☐	Some challenge ☐	Substantial challenge ☐	Unknown ☐

	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown
To what extent did involvement in the AFRO-Move Network help with acceptability of implementation at the site?	☐	☐	☐	☐

	No challenge	Some challenge	Substantial challenge	Unknown
To what extent was inclusion or enrollment of participants a challenge?	☐	☐	☐	☐

	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown
To what extent did being in the AFRO-Move Network support the inclusion or enrollment of participants?	☐	☐	☐	☐

	No challenge	Some challenge	Substantial challenge	Unknown
To what extent was ensuring participants represented the source population a challenge?	☐	☐	☐	☐

	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown
To what extent did being in the AFRO-Move Network help ensure representation of the source population?	☐	☐	☐	☐

	No challenge	Some challenge	Substantial challenge	Unknown	Not applicable
To what extent was the selection of representative controls (if case-control design) a challenge?	☐	☐	☐	☐	☐

	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown	Not applicable
To what extent did involvement in the AFRO-Move Network help ensure selection of representative controls (if case-control design)?	☐	☐	☐	☐	☐

	No challenge	Some challenge	Substantial challenge	Unknown	Not applicable
To what extent was completion of follow up (if cohort design) a challenge?	☐	☐	☐	☐	☐

	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown	Not applicable
To what extent did involvement with the AFRO-Move Network help ensure completion of follow up (if cohort design)?	☐	☐	☒	☐	☐

	No challenge	Some challenge	Substantial challenge	Unknown
To what extent were local testing practices or availability of tests (e.g., use of PCR tests) a challenge?	☐	☐	☐	☐

	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown
To what extent did being in the AFRO-Move Network benefit local testing practices or availability of tests (e.g., use of PCR tests)?	☐	☐	☐	☐

	No challenge	Some challenge	Substantial challenge	Unknown
To what extent was availability of information on test results a challenge?	☐	☐	☐	☐

	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown
To what extent did involvement in the AFRO-Move Network help with availability of information on test results for your study site?	☐	☐	☐	☐

	No challenge	Some challenge	Substantial challenge	Unknown
To what extent was the individual verification of case status of challenge?	☐	☐	☐	☐

	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown
To what extent did involvement with the AFRO-Move Network help ensure individual verification of case status?	☐	☐	☐	☐

	No challenge	Some challenge	Substantial challenge	Unknown
To what extent was local access or uptake of COVID-19 vaccines a challenge?	☐	☐	☐	☐

	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown
To what extent did involvement in the AFRO-Move network benefit local access or uptake of COVID-19 vaccines?	☐	☐	☐	☐

	No challenge	Some challenge	Substantial challenge	Unknown
To what extent was availability of information on vaccination status (including confirmation that doses were not received) a challenge?	☐	☐	☐	☐

	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown
To what extent did involvement in the AFRO-Move Network help with availability of information on vaccination status (including confirmation that doses were not received)?	☐	☐	☐	☐

	No challenge	Some challenge	Substantial challenge	Unknown
To what extent was individual verification of vaccination status a challenge?	☐	☐	☐	☐

	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown
To what extent did involvement in the AFRO-Move Network help with individual verification of vaccination status?	☐	☐	☐	☐

	No challenge	Some challenge	Substantial challenge	Unknown
To what extent was availability of information on age, location, calendar time a challenge?	☐	☐	☐	☐

	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown
To what extent did involvement in the AFRO-Move network help with availability of information on age, location, calendar time?	☐	☐	☐	☐

	No challenge	Some challenge	Substantial challenge	Unknown
--	--------------	----------------	-----------------------	---------

To what extent was availability of information on underlying health conditions a challenge?	☐	☐	☐	☐
	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown
To what extent did involvement in the AFRO-Move network help with availability of information on underlying health conditions?	☐	☐	☐	☐
	No challenge	Some challenge	Substantial challenge	Unknown
To what extent was availability of information on prior infection a challenge?	☐	☐	☐	☐
	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown
To what extent did involvement in the AFRO-Move network help with availability of information on prior infection?	☐	☐	☐	☐
	No challenge	Some challenge	Substantial challenge	Unknown
To what extent was accrual of enough data for analysis of VE a challenge?	☐	☐	☐	☐
	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown
To what extent did involvement in the AFRO-Move Network help with accrual of enough data for analysis of VE?	☐	☐	☐	☐
	No challenge	Some challenge	Substantial challenge	Unknown
To what extent was data analysis support a challenge?	☐	☐	☐	☐
	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown
To what extent did involvement in the AFRO-Move network help with data analysis support?	☐	☐	☐	☐
	No challenge	Some challenge	Substantial challenge	Unknown
To what extent was support for writing for publication a challenge?	☐	☐	☐	☐

	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown
To what extent did involvement in the AFRO-Move network help with writing for publication?	☐	☐	☐	☐
	No challenge	Some challenge	Substantial challenge	Unknown
To what extent was dissemination of findings a challenge?	☐	☐	☐	☐
	No additional benefit	Some additional benefit	Substantial additional benefit	Unknown
To what extent did involvement in the AFRO-Move network help with dissemination of findings?	☐	☐	☐	☐
Did you identify any other site challenges that are not listed above?	☐ Yes ☐ No			
Please explain each additional challenge and its level of significance (e.g. somewhat of a challenge, a substantial challenge, etc).				
For each additional challenge, please explain how and to what extent the network may have contributed to addressing it (network involvement added some benefit, network added substantial benefit, etc.).				
Did you identify any other site benefits from the AFRO-MoVE network that are not listed above?	☐ Yes ☐ No			
Please explain.				

Please indicate your perceived level of impact for each of the following activities held by the Secretariat.

	Not at all impactful	Somewhat impactful	Substantially impactful	N/A, I did not participate in this activity
Direct technical assistance from AFRO-MoVE secretariat to countries to plan and implement studies	☐	☐	☐	☐
Network webinars and workshops	☐	☐	☐	☐
Sharing of generic protocols and templates	☐	☐	☐	☐

Coordination across WHO
member states funding hub

☐☐☐☐

Are there any other activities held by the Secretariat
that were not mentioned above but you felt were
impactful?

☐ Yes ☐ No

Please list the activity(ies) and their perceived
level of impact (e.g. somewhat impactful,
substantially impactful, etc).

How could the network meetings organized by the
AFRO-MoVE Secretariat have been improved to better
support the design, implementation, and analysis at
study sites, if at all?

How could the direct technical assistance provided by
the AFRO-MoVE Secretariat have been improved to better
support the design, implementation, and analysis at
study sites, if at all?

Did participation within the AFRO-MoVE network
increase your access to or communication with relevant
experts?

☐ Not at all
☐ Somewhat
☐ Significantly

Please list any comments you have surrounding impact
of participation within the AFRO-MoVE Network on
communication with relevant experts.

Do you feel the communications across the network led
by AFRO-MoVE Secretariat could have been improved?

☐ Yes
☐ No

Please elaborate.

Do you feel that the AFRO-MoVE Network was useful in
strengthening capacity for VE studies in your country?

☐ Not at all
☐ Somewhat
☐ Significantly

Do you feel that the AFRO-MoVE Network was useful in
strengthening capacity for VE studies in the AFRO
region?

☐ Not at all
☐ Somewhat
☐ Significantly

Were you overall satisfied by the performance of the
AFRO-MoVE network, considering both network processes
and VE outcomes?

☐ Yes
☐ No

Please elaborate.

Please rate your level of interest in your continuing
to engage in the AFRO-MoVE network.

☐ Not at all interested
☐ Somewhat interested
☐ Interested
☐ Very interested

Briefly explain why it is that you were not involved or minimally involved in activities supported by the AFRO-MoVE network.

Please indicate what you believe to have served as the biggest challenge in establishing your VE study site?

Do you feel that the AFRO-MoVE network strengthens the ability of countries in the region to conduct VE studies for other pathogens in the future?

- ☐ Not at all
☐ Somewhat
☐ Significantly
-

Please elaborate.

Are there other technical areas or efforts that you think AFRO-MoVE would be well-positioned to support in the future?

- ☐ Yes
☐ No
-

Please elaborate.

Is there any additional feedback you feel is important for us to capture regarding the network (satisfaction, engagement, benefits, challenges, future participation, etc), that has not been covered already in this survey?

- ☐ Yes
☐ No
-

Please elaborate.

Key Informant Interview

Please complete the survey below. Thank you!

- 1) Please list your name? First name first

- 2) Please state your title?

- 3) Please indicate your organization

- 4) Please indicate your country of work?

- 5) Kindly type your email address

- 6) Please characterize your relationship to the AFRO-MOVE network

☐ Funder
☐ Scientific Steering Committee
☐ Network Secretariat
☐ VE Study Site
☐ Other Network Member
- 7) What has been your role within your organization and how does it relate to the AFRO-MoVE network?

- 8) Did you participate in AFRO-MoVE network calls, webinars, or other activities? If yes, which ones?

- 9) Based on your experience with any delays to establishing and conducting VE studies, is your organization now better prepared to establish new studies in a timely manner?

- 10) How might the AFRO-MoVE network provide support to network members in the future to ensure that VE studies for SARS-CoV-2 or other pathogens are established and conducted in a timely manner?

- 11) What challenges did your country's study site face [OR did network-supported studies face] and how have these been addressed?

- 12) Have any of the AFRO-MoVE-led network meetings, technical assistance, or materials helped you address any of these challenges?

- 13) Were there any barriers or issues with your country's VE study [OR generally among network supported studies] that you were NOT able to address?

-
- 14) Would your organization have been able to establish and conduct a VE study for SARS-CoV-2 without support from the AFRO-MoVE network? Why or why not? _____
-
- 15) Is the AFRO Region better positioned to carry out VE studies for SARS-CoV-2 and other pathogens as a result of the AFRO-MoVE network's establishment and resulting activities? _____
-
- 16) For countries or study sites that initiated VE studies but have been unable to meet their objectives, could the AFRO-MoVE network have provided other forms of support to mitigate these challenges? _____
-
- 17) Are the findings of the study useful for COVID-19 policy in your country? How could this be improved (consider issues of timelines, communication/dissemination, etc.) ? _____
-
- 18) To what extent do you think the partnerships or collaborations initiated within AFRO-MoVE will be sustained into the future? _____
-
- 19) What are key lessons from AFRO-MoVE network work thus far that you think need to be shared with others? _____
-
- 20) What has worked well, or not worked well for your study site? _____
-
- 21) What are ways in which you see the AFRO-MoVE network continuing to support your organization and future VE studies in the region? _____